An Open Letter to our Customers from WuXi AppTec Leadership

For more than 20 years, WuXi AppTec has enabled thousands of customers across the pharmaceutical and life sciences industries to discover, develop, and manufacture new medicines to benefit patients. We have always been guided by our core value of “doing the right thing and doing it right.” And we remain committed to this ethos despite recent unfounded and misleading claims about our company. Like many of you, we are concerned by a misguided U.S. legislative initiative to target our company without a fair and transparent review of the facts. We are equally concerned by the serious impact the unwarranted allegations and harmful actions would have on patients who rely on the life-saving and innovative work our customers perform in the United States and around the world. We want to be clear and set the record straight: WuXi AppTec does not pose a national security risk to any country. While the U.S. government has determined that certain companies do pose such a risk to the United States and has imposed sanctions against them, WuXi AppTec has never been subject to any such determination or sanction. We welcome regulatory oversight of our industry, including the proposed evaluation of biotech companies in the recent legislation. But we strongly object to blanket allegations and preemptive actions against our company without due process. WuXi AppTec has a strong track record of upholding the highest intellectual property, data and privacy protection standards, as well as maintaining the trust of our customers. Our number one priority continues to be providing customers with resources and capabilities to advance discoveries in the life sciences and deliver treatments to those in need. As deliberations on this legislation continue, we are actively correcting the unfounded and misleading claims about our company. We are confident that upon considering the facts, U.S. lawmakers will understand that WuXi AppTec does not in any way pose a national security risk to any country. Instead, we serve as a valued contributor to the pharmaceutical and life sciences industries. Sincerely, Ge Li, Ph.D., Chairman & CEO Minzhang Chen, Ph.D., Co-CEO Steve Yang, Ph.D., Co-CEO

About Us

Enabling Innovation

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Services and Solutions

An Open Enabling Platform

Enabling more than 6,000 innovative customers from more than 30 Countries

icon

Small Molecule Drug R&D and Manufacturing

icon

Cell Therapy
and Gene Therapy

icon

Drug R&D and Medical
Device Testing

icon

Clinical
Services

icon

Small Molecule Drug R&D and Manufacturing

Company Platform

Enabling Anyone, Any Company

To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry

WuXi Chemistry

Provides CRDMO services
for new drug development from discovery to commercial

WuXi Biology

A full spectrum of biology services and solutions
supporting stand-alone and integrated projects

WuXi Testing

Seamless drug and medical device testing services
from preclinical testing to clinical trials

WuXi Advanced Therapies

Global CTDMO
offering an integrated end-to-end solution to accelerate time to market for cell and gene therapies

News

The Latest News about WuXi AppTec

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022

Careers

Welcome to

Our Team

Become Part of Creating a Better Life

Investors

The Latest Financial Reports, Announcements and Resources